INTRODUCTION
Dendritic arborization determines the synaptic connectivity and input integration that are necessary for proper network function. As such, alterations in dendritic morphology affect network activity and stability (Hä usser et al., 2000; Jan and Jan, 2010; Sjö strö m et al., 2008) . Anomalies in dendritic morphology are observed in and contribute to the pathology of many neurodevelopmental and neurodegenerative disorders (Dierssen and Ramakers, 2006; Jan and Jan, 2010; Nestor and Hoffman, 2012) . In particular, abnormal dendritic complexity is a shared feature of neurodevelopmental disorders associated with cognitive and social impairments, and altered tuberous sclerosis complexmammalian target of rapamycin (TSC-mTOR) signaling (Crino et al., 2006; Feliciano et al., 2013a; Kwiatkowski and Manning, 2005; Kwon et al., 2006) . TSC is one such neurodevelopmental disorder. However, the molecules responsible for increased dendritic arborization in TSC remain elusive.
TSC is due to mutations in either TSC1 or TSC2, whose protein products form a functional complex. The major function of the TSC complex is to repress the activity of Ras homolog enriched in brain (Rheb), the canonical activator of mTOR complex 1 (mTORC1). Thus, loss of Tsc1 in neurons results in hyperactive mTORC1 and morphological changes such as increased soma size and dendritic hypertrophy (Feliciano et al., 2011 (Feliciano et al., , 2012 (Feliciano et al., , 2013a Meikle et al., 2007; Neuman and Henske, 2011) . To identify dysregulated genes that may contribute to dendritic overgrowth in TSC, we performed a PCR array from conditional Tsc1 knockout mouse tissue and found that the filamin A gene (Flna) transcript was significantly elevated. Although filamin A (FLNA) has no documented role in dendritic morphogenesis, its well-studied role in cytoskeletal reorganization prompted us to ask whether FLNA might also regulate dendritogenesis and contribute to pathologic dendritic arborization in TSC.
FLNA is a scaffolding protein with actin crosslinking capacity that couples extracellular signaling to the cellular cytoskeleton (Nakamura et al., 2011) . As a result, FLNA regulates diverse aspects of cell development, including filopodia formation in nonneuronal cells (Ohta et al., 1999) , growth cone progression in Drosophila (Zheng et al., 2011) , proliferation of cortical neural progenitors (Carabalona et al., 2012; Lian et al., 2012) , and migration of diverse cell types (Baldassarre et al., 2009; Cunningham et al., 1992; Fox et al., 1998; Xu et al., 2010) including developing cortical neurons (Nagano et al., 2004; Sarkisian et al., 2006 Sarkisian et al., , 2008 . Consistent with a role in neurodevelopment, human FLNA loss-of-function mutations result in the brain disorder Xlinked periventricular nodular heterotopia (Eks xio glu et al., 1996; Fox et al., 1998) . Despite documented roles for FLNA in cell morphogenesis, neurite extension, and neural growth cone dynamics (Letourneau and Shattuck, 1989) , it remains unknown whether FLNA also regulates dendritic morphogenesis.
Here, we set out to address whether FLNA contributes to normal dendritic patterning and pathological dendritic arborization in TSC using combined genetic, pharmacologic, and physiological approaches. We first verified our array data by confirming that FLNA levels are elevated in Tsc1 null neurons. We then established a physiological role for FLNA in normal dendritic morphogenesis. Next, we found that normalizing FLNA levels in Tsc1 null neurons prevented abnormal dendritic morphology. We then sought to identify the molecular mechanism responsible for elevated FLNA levels in TSC. Although hyperactive mTORC1 signaling is known to increase protein translation and our initial observation was that Flna transcription is increased in Tsc1 null neurons, we were still surprised to find that FLNA expression was resistant to mTOR blockers. Therefore, we examined ERK1/2 because Flna transcription is predicted to be ERK1/2 dependent (D'Addario et al., 2002; Tan and Khachigian, 2009 ) and ERK1/2 is hyperactive in TSC individuals and mouse models of TSC (Magri et al., 2011; Maldonado et al., 2003) . We found that a MEK-ERK1/2-dependent increase in FLNA levels contributes to pathological dendritic complexity in TSC. In addition, blocking MEK-ERK1/2 activity in Tsc1 null neurons after dendritic defects have been established is sufficient to rescue the dendritic phenotype. Collectively, our findings identify FLNA as a player in dendritic morphogenesis and uncover an mTORC1-independent, ERK1/2-dependent increase in FLNA downstream of TSC1/TSC2 signaling that contributes to dendritic anomalies in Tsc1 null neurons. Because mTORC1 inhibition can partially rescue dendritic pathology without rescuing FLNA levels, we propose that elevated MEK-ERK1/2-FLNA and hyperactive mTORC1 independently contribute to dendritic anomalies in TSC.
RESULTS

Identification of Elevated Flna mRNA in Tsc1
null Neurons
To identify genes whose altered expression might contribute to morphological dysfunction in disorders of the TSC-mTORC1 signaling pathway, we used a quantitative RT-PCR (qRT-PCR) array to assess the levels of 84 neurogenesis genes in Tsc1 null neuron-containing olfactory bulbs (OBs). To generate Tsc1 null neurons in the OBs, we exploited the fact that neural stem cells located in the subventricular zone (SVZ) along the lateral ventricle generate OB neurons postnatally that are easily electroporated neonatally (Boutin et al., 2008; Lacar et al., 2010; Platel et al., 2010) . We electroporated a Cre recombinase-encoding plasmid (Cre) at postnatal day (P) 0 into SVZ neural stem cells of Tsc1 Table S1 available online for a list of plasmids). In these mice, Cre electroporation led to tdTomato expression and excision of the floxed Tsc1 allele in both neural stem cells and their progeny, as we have previously reported (Feliciano et al., 2012 ; data not shown). We used Tsc1 fl/mut mice to match the genetics of TSC individuals who are heterozygous for one of the TSC alleles (TSC1 or TSC2) but harbor neurons that lose the second TSC allele during development (Au et al., 2004; Feliciano et al., 2013a; Kwiatkowski and Short, 1994) . As a control, we used the contralateral OB that does not contain electroporated cells. We performed a qRT-PCR array on messenger RNA (mRNA) from electroporated (ipsilateral) P14 OBs and from contralateral (control) OBs (n = 2 mice per condition; Figure 1C ). Of the 84 genes in the array, we found that the mRNA of 5 genes (Alk, Drd5, Flna, Bmp8b, and Gdnf) were upregulated by >1.5-fold in both Tsc1 null samples compared to control samples while several mRNAs were downregulated ( Figure 1D and Table S2 ). We focused on the actin crosslinking protein FLNA because of its proposed role in neurite morphogenesis. We confirmed the increase in Flna gene expression by qRT-PCR of Flna mRNA from the OBs containing Tsc1 null neurons and the contralateral unelectroporated Tsc1 fl/mut OBs ( Figure 1E ). Using Gapdh as a control, we found that Flna mRNA levels were $4-fold higher in the OBs containing Tsc1 null neurons compared to the control OBs (n = 3 mice, p < 0.05, Student's t test; Figure 1E ). (Figure 2A ). Figure S1 and Tables S1 and S2.
We first verified that Flna transcript levels are elevated in RTsc1 cKO using qRT-PCR. Flna mRNA was significantly increased in P7 RTsc1 cKO compared to RTsc1 cHet cortices (by 360%, n = 4 mice, Student's t test; Figure 2B ). Second, we verified that Tsc1 deletion increases mTORC1 activity and tested whether FLNA protein levels were increased in RTsc1 cKO mice. We immunoblotted tissue from P7 cortex (n = 4 mice) and P14 OB (n = 5 mice) and assessed mTORC1 by p70 S6 kinase 1 phosphorylation (pS6K1), a direct target of mTORC1, and phosphorylated ribosomal protein S6 (pS6), a target of S6K1. Using ERK1/2 or amido black (i.e., total protein) as a loading control, we found that both the cortex and OB of RTsc1 cKO mice display significant increases in mTORC1 activity and FLNA expression without alterations in relative FLNA phosphorylation (one-way ANOVA with Tukey posttest throughout the article unless mentioned otherwise; p values are given in figure legends for Figures 2C, 2D , and 2F). FLNA belongs to a family of actinbinding proteins, of which only one other member, FLNB, is expressed in the central nervous system (Takafuta et al., 1998) . FLNB levels were not altered in cortices or OBs of RTsc1 cKO mice ( Figures 2D and 2F ). Next, we used an in vitro system to rule out that increased FLNA is a nonspecific consequence of seizure activity that occurs in RTsc1 cKO mice (Magri et al., 2011) . Neuro2a cells were transfected with either a plasmid encoding constitutively active Rheb (Rheb CA ), a downstream target of the TSC complex that activates the mTORC1 pathway, or a control plasmid encoding green fluorescent protein (GFP) ( Figure 2C ) (Lafourcade et al., 2013; Maehama et al., 2008) . Immunoblots performed 48 hr posttransfection revealed that Rheb CA transfection leads to a significant increase in mTORC1 activity as indicated by increased levels of pS6K1 and pS6 (n = 3 cells each; Figures  2E, 2F , and S1). Rheb CA transfection also led to a significant increase in FLNA levels without affecting its degree of phosphorylation and did not alter FLNB levels ( Figures 2E and 2F ). As such, disruptions of the TSC pathway can lead to elevated FLNA levels in the absence of seizures. Finally, we obtained prefrontal cortical tissue from human male patients with TSC and age-matched male individuals without any known pathology (Table S3) . TSC patients displayed variability in the TSC1 or TSC2 levels (Figures 2G and 2H) . Such variability among TSC patients may be accounted for by differences in several parameters including (but not limited to) the ages of the patients, the degree of seizure activity and drug treatment, the type of mutation, and the degree of gliosis. Despite the variability, four out of five TSC patients displayed FLNA levels above those of control patients (Figures 2G and 2H) and contributed to a significant net increase in FLNA levels compared to control patients (p < 0.001, Student's t test; Figure 2I) . Collectively, these data show that FLNA gene expression and protein levels are increased in cells with decreased TSC function in mouse models and humans, thus warranting us to examine the role of FLNA in dendritic development and alterations in TSC.
An Optimal FLNA Level of FLNA Expression Is Required for Proper Dendritic Morphogenesis
To investigate whether FLNA is a physiologic regulator of dendritic morphogenesis in vivo, we used neonatal electroporation to manipulate FLNA levels in developing neurons (see Figure 1A for diagram). FLNA and control plasmids were electroporated into wild-type SVZ cells of P0 wild-type mice using the method outlined in Figure 1A . During division, electroporated neural progenitors pass their exogenous plasmids on to neuroblasts, which migrate to and integrate into the OB. By 2 weeks, these neuroblasts differentiate into GABAergic interneurons with both an apical and a basal dendrite. We assessed the complexity and length of the basal dendrites of transfected neurons in vivo at 14 and 28 days postelectroporation by Sholl analysis of coronal sections from littermate mice ( Figure 3A) .
To evaluate the effect of FLNA overexpression, we used a plasmid encoding FLNA followed by GFP driven by an internal ribosomal entry site (pCAG-FLNA) and a plasmid encoding GFP alone (pCAG-GFP) as a control. pCAG-FLNA was validated by transfecting Neuro2a cells ( Figure 3B ). To determine whether pCAG-FLNA was sufficient to increase FLNA levels in neurons, we electroporated pCAG-FLNA or pCAG-GFP in vivo into SVZ cells at P0 and cultured transfected OB neurons 7 days postelectroporation. Transfected neurons were visualized by cotransfecting with a plasmid encoding tdTomato (pCAG-tdTomato) in addition to pCAG-FLNA or pCAG-GFP because the GFP fluorescence in pCAG-FLNA vector was faint. Because electroporation only transfects a subset of cells, the cultures contained a mix of tdTomato+/FLNA+ neurons or tdTomato+/GFP+ neurons with nontransfected neurons ( Figure S2 ). tdTomato-expressing neurons transfected with the pCAG-FLNA displayed increased FLNA immunostaining compared to surrounding tdTomatonegative cells ( Figure S2A ).
Having validated the pCAG-FLNA plasmid, we tested whether neuronal FLNA overexpression alters dendritic development in vivo. Sholl analysis revealed that FLNA overexpression significantly alters the basal dendrite by increasing dendritic complexity, total dendritic length, and the length of the longest dendrite (i.e., maximum length) at P14 (two-way repeated-measures ANOVA with post hoc Bonferroni test, n = 28 neurons, 4 mice each; . At P28, FLNA-overexpressing neurons displayed a persistent increase in dendritic complexity and a concomitant increase in total dendritic length; however, the maximum length was similar to that of controls (n = 24 neurons, 4 mice each; Figures 3C-3G).
We next evaluated the consequence of decreasing FLNA levels on dendritic development. To do so, we utilized a GFP-expressing plasmid that also encodes a short hairpin RNA (shRNA) directed against either FLNA (shFLNA) or luciferase (shLuc, control). In Neuro2a cells, shFLNA significantly decreased FLNA protein levels relative to shLuc (n = 3 cells; Figure 3H ). Similarly, newborn neurons cultured 7 days after in vivo coelectroporation of shFLNA and pCAG-tdTomato displayed decreased FLNA expression compared to surrounding nontransfected neurons ( Figure S2B ). Unexpectedly, shFLNA-electroporated neurons also displayed increased dendritic complexity at P14 in vivo compared to shLuc-transfected neurons (n = 50 neurons each, 8 mice each; Figures 3I and 3J ). The increased dendritic complexity was accompanied by significantly increased total and maximum dendritic length ( Figure 3K ). This effect was unlikely to be due to an off-target effect of shFLNA, because it was prevented by cotransfection with an shFLNA-resistant human FLNA-encoding plasmid (n = 35 neurons each, 6 mice each; Figures 3L-3O) .
Collectively, these data show that both elevated and decreased FLNA expression result in increased dendritic complexity of wild--type newborn neurons. This suggests that an optimal level of FLNA is required for proper dendritic morphogenesis. S3A and S3B) . This is likely due to the progressive dilution of the shFLNA plasmid in later born Tsc1 null neurons subsequent to multiple rounds of neural progenitor division . We also found that knocking down FLNA in Tsc1 het neurons likewise reduced their dendritic complexity and total dendritic length (n = 34 neurons each, 4 mice; Figures S3C-S3E ).
Reducing FLNA Levels in Tsc1
null Neurons Normalizes Synaptic Event Frequency Abnormal dendritic patterning should alter network integration and synaptic activity. In order to evaluate the physiological consequences of altered dendritic complexity, we obtained patch clamp recordings of neurons between P21 and P25. We found that Tsc1 het and Tsc1 null neurons with shLuc or shFLNA displayed current-induced action potentials ( Figure 5A Figures 5D and 5E ). This finding is consistent with an increased total dendritic length providing more area for synaptic contacts. Notably, knocking down FLNA normalized the frequency of synaptic inputs consistent with its normalization of dendritic morphology and length. However, it did not prevent the changes in resting membrane potentials or cell conductance (n = 7 Tsc1 null neurons with shFLNA; Figures 5B, 5C, and 5E) .
Collectively, these data suggest that FLNA contributes to an increase in dendritic complexity and total length, and to an associated increase in synaptic input density in Tsc1 null neurons. Normalizing FLNA levels in Tsc1 null neurons is sufficient to prevent these dendritic and synaptic anomalies.
Hyperactive MEK1/2, Not mTORC1, Is Responsible for Increased FLNA Downstream of TSC-Rheb Because the mTORC1 pathway is the canonical pathway increased in TSC, we examined whether elevated FLNA levels following TSC1 loss are mTORC1 dependent. RTsc1 cKO mice
were treated with the mTORC1 blocker, rapamycin at a dose of 0.5 mg/kg (four injections every other day from P7 to P14). Rapamycin significantly reduced mTORC1 activity in OB tissue containing Tsc1 null cells, as indicated by reduced pS6 levels; however, rapamycin had no effect on FLNA levels (n = 3 mice each; Figures  6A and 6B ). FLNA levels were similarly unchanged in rapamycintreated and RTsc1 cHet mice, despite significantly reduced pS6.
Because in vivo treatments can be associated with variable drug titers, we replicated our in vivo mTOR inhibitor findings in an in vitro system. Once again, Neuro2a cells transfected with Rheb CA displayed increased FLNA expression (Figures 6C and 6D; see Figure 2 ). In these cells, elevated pS6 was significantly reduced by the mTORC1 inhibitor rapamycin and the mTOR kinase inhibitor Torin 1 (Figures 6C and 6D ). We tested Torin 1 because it inhibits mTOR kinase activity directly, thereby inhibiting both mTORC1 and mTORC2. Torin 1 inhibits mTOR activity more uniformly, whereby rapamycin preferentially blocks mTOR activity toward S6K1 (Choo et al., 2008; Thoreen et al., 2009) . Despite reducing mTOR activity, neither rapamycin nor Torin 1 significantly reduced FLNA levels in Rheb CA -transfected Neuro2a cells ( Figures 6C and 6D ). These data suggest that both Tsc1 deletion and Rheb hyperactivity increase FLNA expression in an mTOR-insensitive manner.
Although the mTORC1 pathway is the best studied pathway in TSC, the MEK-ERK1/2 pathway is another critical regulator of cell growth and development that has been shown to be hyperactive in TSC (Ché vere-Torres et al., 2012; Magri et al., 2011; Maldonado et al., 2003) . In addition, FLNA transcription is predicted to be under the regulation of the MEK-ERK1/2 pathway (D' Addario et al., 2002 Addario et al., , 2006 Tan and Khachigian, 2009 ). Therefore, we tested whether elevated FLNA in RTsc1 cKO mice is due to hyperactive MEK-ERK1/2 pathway activity. Consistent with previous findings, we found that ERK1/2 activity is significantly increased in 
RTsc1
cKO mice (Magri et al., 2011 ; and validated here, n = 3 mice;
Figures 6A and 6B). In vitro, Rheb CA also increased MEK1-ERK1/2 activity as assessed with pERK1/2 ( Figures 6C and 6D) . Therefore, we hypothesized that hyperactive MEK-ERK1/2 pathway activity, not mTORC1 activity, is responsible for elevated FLNA downstream of Tsc1 deletion and Rheb CA overexpression.
To test this, we first treated Rheb CA -transfected Neuro2a cells with two MEK1 inhibitors, PD0325901 and U0126. Control cells Figure S3 and Table S1 and S4.
were treated with either vehicle or U0124, the inactive form of U0126. The concentration of MEK1 inhibitors used in these experiments was determined by testing a range of concentrations and immunoblotting for pERK1/2 (n = 3 cells; Figure S4) . Consistent with our hypothesis, both U0126 and PD0325901 significantly reduced MEK-ERK1/2 pathway activity as well as FLNA levels ( Figures 6C and 6D) . Critically, neither MEK1 inhibitor altered mTORC1 activity, as demonstrated by persistently elevated pS6 levels ( Figures  6C and 6D) . Thus, MEK1 inhibition is sufficient to reduce FLNA levels in the context of elevated mTORC1 signaling. Collectively, these data suggest that, although mTOR and MEK-ERK1/2 activities are increased in parallel subsequent to Tsc1 deletion or Rheb hyperactivation, elevated FLNA expression is due to elevated MEK-ERK1/2 and not mTOR activity (model in Figure 6E ). We next sought to establish a causal relationship between MEK-ERK1/2-FLNA and the dendritic abnormalities in the context of TSC.
Hyperactive MEK-ERK1/2 Signaling Increases Dendritic Complexity via FLNA in Tsc1
First, we assessed whether increasing MEK-ERK1/2 activity in wild-type neurons is sufficient to recapitulate the dendritic abnormalities seen in Tsc1 null neurons; and, if so, whether MEK-ERK1/2 dendritic defects require upregulation of FLNA expression ( Figure 7A for a diagram of vectors used). To increase ERK1/2 activity, we obtained a constitutively active MEK1 (MEK1 CA , DN-S222D mutant; Mansour et al., 1994) . In Neuro2a cells, MEK1 CA led to increased MEK-ERK1/2 activity and FLNA expression ( Figure 7B ). In cultured wild-type cortical neurons, MEK1 CA expression led to a significant increase in MEK-ERK1/ 2 activity and FLNA transcription, which was measured using a luciferase reporter under a mouse Flna reporter (n = 6 sets of culture; Figures 7C and 7D , increase in MEK-ERK1/2 activity not shown). We therefore assessed the effect of hyperactive MEK1/2 activity on dendritogenesis in vivo by electroporating the MEK1 CA -encoding plasmid into neonatal progenitor cells as described in Figure 1 . MEK1 CA expression in vivo led to a significant increase in the dendritic complexity and total dendritic length of newborn neurons at both P14 (n = 39 neurons per condition, 4 mice each; Figures 7E-7G ) and P28 (n = 4 mice; data not shown). Notably, knocking down FLNA in wild-type neurons expressing MEK1 CA was sufficient to normalize dendritic morphology ( Figures 7E-7G ). These data suggest that the MEK-ERK1/2 pathway can regulate dendritic patterning via FLNA.
These results suggest that hyperactive MEK-ERK1/2 drives pathologic FLNA expression and contributes to dendritic dysmorphogenesis in TSC. To address this possibility, we examined whether hyperactive MEK-ERK1/2 activity underlies abnormal dendritic morphology in Tsc1 null neurons, using a dominantnegative MEK1 vector (MEK1 DN , K97M mutant; Mansour et al., 1994) . In Neuro2a cells, transfection of MEK1 DN decreased pERK1/2 and FLNA levels ( Figure 7B ). In vivo, coelectroporation of MEK1 DN and Cre prevented the increases in dendritic complexity and length of Tsc1 null cells seen in control (GFP) electroporated Tsc1 mull cells when analyzed at both P14 (n = 24-27 neurons per condition, 4 mice each; Figures 7H-7J ) and P28 (n = 31 neurons per condition, 4 mice; Figures S5A-S5C) . Collectively, these data provide strong evidence that MEK-ERK1/2 contributes to dendritic abnormalities in Tsc1 null neurons by increasing FLNA expression.
Pharmacological Inhibition of MEK-ERK1/2 or mTORC1 Activity in Tsc1 null Neurons Rescues Dendritic Defects
As we previously showed that mTOR inhibition partially rescues dendritic hypertrophy (Lafourcade et al., 2013) , we wondered whether reducing MEK1-ERK1/2 activity also recues dendritic defects of Tsc1 null cells. Because coincident electroporation of MEK DN and Cre does not allow use to distinguish rescue of the dendritic phenotype from prevention of the phenotype, we used a pharmacological approach to inhibit MEK1-ERK1/2 activity after the establishment of dendritic abnormalities. Specifically, we tested whether the MEK1/2 blocker PD0325901 can rescue FLNA levels and dendritic defects in Tsc1 null neurons.
PD0325901 used at 1 mg/kg in vivo significantly decreased ERK1/2 activity in the OB of Tsc1 fl/mut mice treated from P14 to P28 (n = 4 mice; Figures S6A and S6B) .
To test the ability of PD0325901 to decrease FLNA levels in Tsc1 null neurons, dissociated neurons from RTsc1 fl/mut and RTsc1 fl/wt mice were transfected with a Cre-encoding plasmid and cultured for 7 days in the presence of PD0325901 (2 mM; Figure 8A ). PD0325901 significantly decreased FLNA levels, albeit not to the levels seen in Tsc1 het neurons (n = 3 sets of cultures; Figures 8B and 8C) . Notably, in vivo treatment with PD0325901 (1 mg/kg) from P14 to P28 significantly decreased the dendritic complexity and total dendritic length of Tsc1 null neurons ( Figures 8A, 8D , and 8E). A similar treatment with rapamycin (0.5 mg/kg, every other day), which decreased mTORC1 activity ( Figure S6C ), also significantly decreased dendritic complexity and normalized dendritic length of Tsc1 null neurons compared to Tsc1 het neurons ( Figures 8D-8F ). These data suggest that increased mTORC1 and MEK-ERK1/2 signaling independently contributes to dendritic defects in Tsc1 null neurons.
Based on our data, blocking either pathway is sufficient to significantly prevent the dendritic defects. 
DISCUSSION
Here we report that FLNA regulates dendritic morphogenesis. Moreover, FLNA overexpression underlies pathologic morphological and physiological defects in a mouse model of the human disorder TSC. We found that increased FLNA levels in our TSC models are MEK-ERK1/2 dependent, and as such, reducing MEK-ERK1/2 signaling was sufficient to significantly rescue the dendritic defects. Additionally, early interventions that decrease FLNA levels in either Tsc1 null or hyperactive MEK-ERK1/2 conditions are sufficient to prevent abnormal dendritic development. Based on our findings, it is clear that conditions that push FLNA expression out of a narrow physiologic range promote abnormal dendritic patterning. To our surprise, both increasing and decreasing FLNA levels leads to increased dendritic complexity in newborn neurons. Although unexpected, this finding is not unreasonable, considering that both high and low levels of FLNA expression impair cell migration, implying a bell-shaped function for optimal FLNA expression (Cunningham et al., 1992; Sarkisian et al., 2008) . Similar to cell migration, deviation from optimal FLNA expression in either direction results in hypertrophic dendrites. How both under-and overexpression of FLNA produce the same phenotype is not clear; however, it is notable that FLNA has multiple physiologic functions. Not only is FLNA involved in cytoskeletal reorganization by binding to and crosslinking actin, but it also serves as a signaling and scaffolding protein that links the cytoskeleton to membrane and signaling molecules (Feng and Walsh, 2004; Razinia et al., 2012; Stossel et al., 2001) . It is possible that these distinct FLNA functions independently (E) A simplified model of TSC-mTOR-MEK-FLNA and the sites of actions of drugs and plasmids used for data acquisition. Dotted lines indicate that the mechanisms linking Rheb to MEK1/2 and FLNA remain unknown. *p < 0.05; **p < 0.01; ***p < 0.001; NS, not significant. Error bars correspond to SEM. See also Figure S4 and Tables S1 and S4. contribute to dendritogenesis in differing ways. Understanding specifically how both under-or overexpression of FLNA lead to dendritic hypertrophy is the focus of ongoing study.
Nonetheless, overexpression of FLNA in Tsc1 null neurons contributes to increased dendritic complexity, as indicated by the fact that normalizing FLNA levels rescues dendritic complexity. Figure S5 and Tables S1 and S4.
Tsc1 null cells are enlarged (Feliciano et al., 2013a) , suggesting that elevated FLNA could be secondary to a general upregulation of cytoskeletal proteins; however, we found that this is not the case, as FLNB levels were unaltered in Tsc1 null cells. Cellular enlargement in TSC is due to hyperactive mTORC1, which promotes both cellular and dendritic hypertrophy (Feliciano et al., 2013a) . Therefore, we expected elevated FLNA to be secondary to mTORC1 hyperactivity.
Counter to our expectations, we found strong evidence that, although Tsc1 deletion in vivo and constitutively active Rheb expression in vitro lead to hyperactive mTORC1 and dendritic hypertrophy, elevated FLNA expression is not downstream of mTORC1. Instead, pathologic FLNA expression in our model of TSC is due to hyperactive MEK-ERK1/2 signaling, and blocking the MEK-ERK1/2 pathway is sufficient to rescue dendritic defects. Speculation about how Rheb and the upstream TSC complex signal to MEK-ERK1/2 to regulate FLNA expression is difficult, given that Rheb signaling outside of mTORC1 is understudied (Jaeschke et al., 2002; Neuman and Henske, 2011) . Conjecture about how MEK-ERK1/2 regulates FLNA expression, however, is more feasible, given that the transcriptional activator serum response factor (SRF) is regulated by ERK (D'Addario et al., 2002 (D'Addario et al., , 2006 Tan and Khachigian, 2009) . SRF is predicted to regulate FLNA expression and indeed, knocking down SRF in Neuro2a cells decreases FLNA expression (L.Z. and A.B., unpublished data). As such, MEK-ERK1/2 hyperactivity in the setting of TSC may promote dendritic hypertrophy via SRF-dependent transcriptional upregulation of the FLNA gene. This is consistent with studies showing that MEK-ERK1/2 activity regulates neurite growth in many cell types (e.g., PC12 cells) and dendritic growth in neurons (Collo et al., 2008; Guo et al., 2012; Ha and Redmond, 2008; Kim et al., 2004; Xu et al., 2014) . Whatever the mechanism, our data showing that MEK1 overexpression leads to FLNA-dependent dendritic hypertrophy in wild-type cells reinforces the finding that reduction of either MEK1 activity (using a dominant-negative vector) or FLNA expression (using shRNA) normalizes dendritic hypertrophy in TSC.
Normalizing dendrites in TSC is not purely cosmetic. Consistent with our previous report in which we overexpressed constitutively active Rheb (Lafourcade et al., 2013) , we found that Tsc1 null neurons display a significant increase in the frequency of miniature synaptic currents. Normalizing dendritic morphology by decreasing FLNA levels in Tsc1 null neurons also restored a normal frequency of synaptic currents. This rescue could not be generalized to all physiologic defects, as Tsc1 null neurons also displayed a relatively depolarized resting membrane potential and a decreased input resistance that were not normalized by FLNA knockdown. These data indicate that electrophysiological defects in TSC are multifactorial.
Finally, it is important to note that we have previously shown that mTORC1 hyperactivity promotes dendritic hypertrophy, and we replicate that finding here. Indeed, we and others have shown that rapamycin reduces hypertrophic dendrites in conditions of hyperactive Rheb or PI3K-AKT, both of which are associated with hyperactive mTORC1 (Feliciano et al., 2013a; Jaworski et al., 2005; Lafourcade et al., 2013) . That the reduction of mTORC1 or MEK1 activity in Tsc1 null cells is sufficient to provide for a dendritic rescue without altering the activity of the other signaling pathway indicates that both mTORC1 and MEK1-ERK1/2 pathways contribute to dendritic hypertrophy in the context of TSC. Thus, our study provides for the possibility that that inhibiting MEK-ERK1/2 activity or normalizing FLNA in TSC may be of therapeutic value. It also suggests that normalizing FLNA may be of benefit in other disorders where the MEK1-ERK1/ 2 pathway is hyperactive, such as autism spectrum disorders (Cuscó et al., 2009; Levitt and Campbell, 2009; Samuels et al., 2009) . Although the study of TSC has historically been mTOR-centric, this work provides a motivation for exploration of additional and complementary approaches to treating TSC. See also Figure S6 and Table S1 . 
EXPERIMENTAL PROCEDURES Animals and Genotyping
Vectors
Vectors used are provided in Table S3 , and additional details are provided in the Supplemental Information.
Western Blot Analysis from Mice and Neuro2a Cells and Antibodies
The Neuro2a mouse neuroblastoma cells were propagated using standard protocol and transfected with Polyjet (SignaGen Laboratories) at 80% confluence. Protein was harvested 48 hr after transfection. Western blotting protocol is detailed in the Supplemental Information. Quantifications were performed using NIH ImageJ software. Primary antibodies are listed in Table S4 . ERK or total protein (Amido Black) signals were used as loading controls and gave similar results. For the phosphorylated form of proteins, data were normalized to the total (unphosphorylated) levels from the same polyvinylidene fluoride membrane. For western blot normalization across blots ( Figure 6C ) within a given experiment, a standard sample was run on each gel (see details in the Supplemental Information).
Drug Treatment
Drug treatment and preparation are detailed in the Supplemental Information. Rapamycin and PD0325901 were purchased from A.G. Scientific (#R-1018) and Seleckbio (#PD0325901), respectively. Torin 1 and ERK blockers (U0126 and U0124) were from Tocris.
Neonatal Electroporation
Electroporations were performed as described elsewhere (Lacar et al., , 2012 Platel et al., 2010; Feliciano et al., 2013b) and are detailed in the Supplemental Information.
Culture of In Vivo Transfected Neurons and FLNA Immunostaining
Seven days following electroporation, OBs were dissected in ice-cold dissection medium (Hank's balanced salt solution with 10 mM HEPES). Following standard dissociation protocol, cells were resuspended in minimum essential medium supplemented with 0.6% glucose and 5% fetal bovine serum and were plated on poly-D-lysine-coated coverslips. The medium was changed to neuronal maintenance medium (neurobasal A medium with 13 B27 and 13 GlutaMAX-1) 3 hr after plating and every other day thereafter. Twenty-four hours after plating, FLNA immunostaining was performed using a standard protocol (Platel et al., 2009 ).
Culture of P0 Cortical Neurons Followed by Nucleofection
The cortex of P0 pups was dissected out to prepare primary neuronal culture as described earlier. Once in cell suspension, neurons were nucleofected using the Mouse Neuron Nucleofector Kit VPG-1001 (Lonza) and following the manufacturer's instructions. Western blot analysis was performed 7 days following nucleofection.
Morphometric Analysis
Images of tdTomato+ basal dendrites were acquired in coronal sections using a Fluoview 1000 confocal microscope and 203 objective. Basal dendrites were traced with simple neurite tracer software (FIJI and GNU GPL, v3) . Sholl analyses were carried out using the number of intersections in 10-mm-increment concentric circles as a measure of morphological complexity. z stacks from three different square fields of view were taken from three different OB sections. Analysis was performed blindly with more than four animals and more than 20 cells per condition. Experiments were performed at two time points to validate that the dendrites did not recover by P28 because of dendritic pruning. We showed the P28 data in Figures S1-S6 because, by P28, the ''rescue'' effect is underestimated due to dilution of the electroporated vectors.
OB Acute Slice Preparation
Coronal OB slices (350 mm) were prepared from anesthetized (Isoflurane 5%) P21-P24 mice using Vibratome 1000. Ice-cold artificial cerebral spinal fluid (ACSF) containing, in millimolars, 124 NaCl, 3 KCl, 1.25 NaH 2 PO 4 , 1 MgSO 4 , 26 NaHCO 3 , 10 dextrose, 2 CaCl 2 , 0.4 ascorbate, 4 Na-lactate, and 2 Na-pyruvate ($290 mOsm/kg, pH 7.2, equilibrated with 95% O 2 /5% CO 2 ) was used during both brain dissection and slicing. Brain slices were kept and used for recordings at 28 C in the ACSF mentioned earlier.
Whole-Cell Recording of OB Granule Cells Fluorescent cells were identified using a 403 water-immersion Olympus LUMPlanFL/IR objective. Whole-cell recordings were performed with an Axopatch 200B amplifier using glass pipettes (4-7 MU) filled with internal solution consisting of the following (in millimolars): 130 KCl, 10 HEPES, 10 di-tris-phosphocreatine, 1 EGTA, 0.1 CaCl 2 , 1.5 MgCl 2 , 4 Na2-ATP, and 0.3 Na-GTP. Liquid junction potential ($4 mV) was not corrected. Miniature synaptic currents were recorded at À70 mV in the presence of 1 mM tetrodotoxin. Data were analyzed with Clampfit 10 (Molecular Devices).
Luciferase Assay
The standard procedure is detailed in the Supplemental Experimental Procedures and was duplicated for each sample. 
